Eric L. Schneider
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Eric L. Schneider has a total of 133 co-authors. Here are the top co-authors by number of shared publications:
- Daniel V. Santi
ProLynx, Inc., 135 Mississippi Street, San Francisco, California 94107, United States
14 shared publications Gary W. Ashley
ProLynx, Inc., 135 Mississippi Street, San Francisco, California 94107, United States
12 shared publicationsRalph Reid
ProLynx (United States), San Francisco, California, United States
8 shared publicationsCharles S. Craik
6 shared publications- Brian R. Hearn
ProLynx , 455 Mission Bay Blvd. South, Suite 145, San Francisco, California 94158, United States
2 shared publications - Charles S. Craik
University of California, San Francisco
2 shared publications
Latest Publications
- 3 February 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
Long-Acting, Longer-Acting, and Ultralong-Acting Antiobesity Peptides
This perspective describes the current status and future prospects of developing long- to ultralong-acting anti-obesity peptides. First, we discuss the current status of lipidation, PEGylation, and Fc fusion technologies to obtain long-acting peptides administered once weekly, and we critique their proposed use for longer dosing intervals. Next, we describe the approach and current results of using macromolecular peptide prodrugs with preprogrammed releasable linkers to achieve longer-acting peptides that can be administered weekly or monthly. Finally, we posit novel modifications of the latter technology that could provide ultralong half-lives of over one month by advantageously exploiting the clearance rates of released peptides. As examples, we posit that prodrugs of low-clearance GLP-1 agonists derived from peptides already modified by lipidation, PEGylation, and Fc fusion could produce ultralong-acting agonists with dosing intervals reaching 3 to even 6 months.
- 3 February 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
Long-Acting, Longer-Acting, and Ultralong-Acting Antiobesity Peptides
This perspective describes the current status and future prospects of developing long- to ultralong-acting anti-obesity peptides. First, we discuss the current status of lipidation, PEGylation, and Fc fusion technologies to obtain long-acting peptides administered once weekly, and we critique their proposed use for longer dosing intervals. Next, we describe the approach and current results of using macromolecular peptide prodrugs with preprogrammed releasable linkers to achieve longer-acting peptides that can be administered weekly or monthly. Finally, we posit novel modifications of the latter technology that could provide ultralong half-lives of over one month by advantageously exploiting the clearance rates of released peptides. As examples, we posit that prodrugs of low-clearance GLP-1 agonists derived from peptides already modified by lipidation, PEGylation, and Fc fusion could produce ultralong-acting agonists with dosing intervals reaching 3 to even 6 months.
- Open Access
- 12 November 2024
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 121 (47)
The limitation of lipidation: Conversion of semaglutide from once-weekly to once-monthly dosing
The objective of this work was to develop a long-acting form of the lipidated peptide semaglutide that can be administered to humans once-monthly. Semaglutide was attached to hydrogel microspheres by a cleavable linker with an expected in vivo release half-life of about 1 mo. After a single subcutaneous dose, the pharmacokinetic parameters of released semaglutide and bodyweight loss were determined in mice, and results were used to estimate the dosing and pharmacokinetics of the released semaglutide in humans. The in vivo half-life of released semaglutide was ~36 d, and a single dose in diet-induced obese mice resulted in a lean-sparing body weight loss of 20% over 1 mo, statistically the same as semaglutide dosed twice daily. Simulations indicated the microsphere-semaglutide would permit once-monthly administration in humans; moreover, it could maintain the therapeutic minimum concentration (C min ) of once-weekly semaglutide with only 75% of the once-weekly maximum concentration (C max ), a feature that could reduce adverse side effects or allow higher dosing. The same approach should enable the conversion of other lipidated peptides from once-weekly to once-monthly administration.
- 12 November 2024
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 121 (47)
Open AccessThe limitation of lipidation: Conversion of semaglutide from once-weekly to once-monthly dosing
The objective of this work was to develop a long-acting form of the lipidated peptide semaglutide that can be administered to humans once-monthly. Semaglutide was attached to hydrogel microspheres by a cleavable linker with an expected in vivo release half-life of about 1 mo. After a single subcutaneous dose, the pharmacokinetic parameters of released semaglutide and bodyweight loss were determined in mice, and results were used to estimate the dosing and pharmacokinetics of the released semaglutide in humans. The in vivo half-life of released semaglutide was ~36 d, and a single dose in diet-induced obese mice resulted in a lean-sparing body weight loss of 20% over 1 mo, statistically the same as semaglutide dosed twice daily. Simulations indicated the microsphere-semaglutide would permit once-monthly administration in humans; moreover, it could maintain the therapeutic minimum concentration (C min ) of once-weekly semaglutide with only 75% of the once-weekly maximum concentration (C max ), a feature that could reduce adverse side effects or allow higher dosing. The same approach should enable the conversion of other lipidated peptides from once-weekly to once-monthly administration.
- Open Access
- 7 October 2024
- Published by MDPI AG in Preprints.org
Long-Acting, Longer-Acting and Ultralong-Acting Peptides
This perspective describes the current status and future prospects of developing long- to ultralong-acting anti-obesity peptides. First, we review the current status of lipidation, PEGylation, and Fc fusion technologies to obtain long-acting peptides administered once weekly. Next, we describe the approach and current results of using macromolecular peptide prodrugs with pre-programmed releasable linkers to achieve longer-acting peptides that can be administered weekly or monthly. Finally, we posit novel modifications of the latter technology that could provide ultralong half-lives of over one month by advantageously exploiting the clearance rates of released peptides. As examples, we posit that prodrugs of low-clearance GLP-1 agonists derived from peptides already modified by lipidation, PEGylation, and Fc fusion could produce ultralong-acting agonists with dosing intervals reaching 3 to even 6 months.
- 7 October 2024
- Published by MDPI AG in Preprints.org
Open AccessLong-Acting, Longer-Acting and Ultralong-Acting Peptides
This perspective describes the current status and future prospects of developing long- to ultralong-acting anti-obesity peptides. First, we review the current status of lipidation, PEGylation, and Fc fusion technologies to obtain long-acting peptides administered once weekly. Next, we describe the approach and current results of using macromolecular peptide prodrugs with pre-programmed releasable linkers to achieve longer-acting peptides that can be administered weekly or monthly. Finally, we posit novel modifications of the latter technology that could provide ultralong half-lives of over one month by advantageously exploiting the clearance rates of released peptides. As examples, we posit that prodrugs of low-clearance GLP-1 agonists derived from peptides already modified by lipidation, PEGylation, and Fc fusion could produce ultralong-acting agonists with dosing intervals reaching 3 to even 6 months.
- Open Access
Synergistic Antitumor Activity of Talazoparib and Temozolomide in Malignant Rhabdoid Tumors
Malignant rhabdoid tumors (MRTs) are among the most aggressive and treatment-resistant malignancies affecting infants, originating in the kidney, brain, liver, and soft tissues. The 5-year event-free survival rate for these cancers is a mere 20%. In nearly all cases of MRT, the SMARCB1 gene (occasionally SMARCA4)—a pivotal component of the SWI/SNF chromatin remodeling complex—is homozygously deleted, although the precise etiology of these tumors remains unknown. While young patients with localized MRT generally show improved outcomes, especially those who are older and have early-stage disease, the overall prognosis remains poor despite optimal standard treatments. This highlights the urgent need for more effective treatment strategies. We investigated the antitumor activity of a PARP1 inhibitor (talazoparib, TLZ) combined with a DNA alkylating agent (temozolomide, TMZ) in MRT xenograft models. PARP1 is a widely targeted molecule in cancer treatment and, beyond its role in DNA repair, it participates in transcriptional regulation by recruiting chromatin remodeling complexes to modulate DNA accessibility for RNA polymerases. To widen the therapeutic window of the drug combination, we employed PEGylated TLZ (PEG~TLZ), which has been reported to reduce systemic toxicity through slow drug release. Remarkably, our findings indicate that five out of six MRT xenografts exhibited an objective response to PEG~TLZ+TMZ therapy. Significantly, the loss of SMARCB1 was found to confer a protective effect, correlating with higher expression levels of DNA damage and repair proteins in SMARCB1-deficient MRT cells. Additionally, we identified MGMT as a potential biomarker indicative of in vivo MRT response to PEG~TLZ+TMZ therapy. Moreover, our analysis revealed alterations in signaling pathways associated with the observed antitumor efficacy. This study presents a novel and efficacious therapeutic approach for MRT, along with a promising candidate biomarker for predicting tumor response.
Open AccessSynergistic Antitumor Activity of Talazoparib and Temozolomide in Malignant Rhabdoid Tumors
Malignant rhabdoid tumors (MRTs) are among the most aggressive and treatment-resistant malignancies affecting infants, originating in the kidney, brain, liver, and soft tissues. The 5-year event-free survival rate for these cancers is a mere 20%. In nearly all cases of MRT, the SMARCB1 gene (occasionally SMARCA4)—a pivotal component of the SWI/SNF chromatin remodeling complex—is homozygously deleted, although the precise etiology of these tumors remains unknown. While young patients with localized MRT generally show improved outcomes, especially those who are older and have early-stage disease, the overall prognosis remains poor despite optimal standard treatments. This highlights the urgent need for more effective treatment strategies. We investigated the antitumor activity of a PARP1 inhibitor (talazoparib, TLZ) combined with a DNA alkylating agent (temozolomide, TMZ) in MRT xenograft models. PARP1 is a widely targeted molecule in cancer treatment and, beyond its role in DNA repair, it participates in transcriptional regulation by recruiting chromatin remodeling complexes to modulate DNA accessibility for RNA polymerases. To widen the therapeutic window of the drug combination, we employed PEGylated TLZ (PEG~TLZ), which has been reported to reduce systemic toxicity through slow drug release. Remarkably, our findings indicate that five out of six MRT xenografts exhibited an objective response to PEG~TLZ+TMZ therapy. Significantly, the loss of SMARCB1 was found to confer a protective effect, correlating with higher expression levels of DNA damage and repair proteins in SMARCB1-deficient MRT cells. Additionally, we identified MGMT as a potential biomarker indicative of in vivo MRT response to PEG~TLZ+TMZ therapy. Moreover, our analysis revealed alterations in signaling pathways associated with the observed antitumor efficacy. This study presents a novel and efficacious therapeutic approach for MRT, along with a promising candidate biomarker for predicting tumor response.
- Open Access
- 29 April 2024
- Published by ScienceOpen
Development of a long acting c-natriuretic peptide suitable for QMo dosing
The C-natriuretic peptide (CNP) analog vosoritide recently became the first drug approved for the treatment of achondroplasia in children, clearly a significant milestone in the history of this rare disease. However, the dosing regimen is very burdensome for the young patients, requiring daily subcutaneous injections for potentially more than a decade. At ProLynx, using our half-life extension technology we have developed a long-acting CNP analog conjugate that demonstrates equal or greater efficacy to vosoritide while at the same time requiring less frequent, more convenient dosing. Our half-life extension technology utilizes β-eliminative linkers to attach a drug to pre-fabricated tetra-polyethylene glycol hydrogel microspheres (tetra-PEG microspheres). When injected subcutaneously, these microspheres act as a stationary depot where the chemistry of the β-eliminative linkers allows for controlled release of the attached drug, which translates directly to control of the plasma half-life. Two microsphere conjugates were prepared with release rates designed to allow once-weekly and once-monthly administration using a highly active, deamidation resistant CNP analog, [Gln 6,14]CNP-38. In vitro studies in mice demonstrated that [Gln 6,14]CNP-38 was slowly released from the conjugates into the systemic circulation with biphasic elimination pharmacokinetics and terminal half-lives of ∼200 h and ∼600 h. In addition, studies in mice using weekly to monthly dosing regimens demonstrated growth comparable to or exceeding daily injections of vosoritide. Further studies in cynomolgus monkeys showed a similarly extended terminal half-live of ~600 h. Simulations of the human pharmacokinetics indicate that plasma levels of [Gln 6,14]CNP-38 could be maintained within the required therapeutic window for monthly dosing intervals, significantly reducing the patient burden from ~30 injections per month to one.
- 29 April 2024
- Published by ScienceOpen
Open AccessDevelopment of a long acting c-natriuretic peptide suitable for QMo dosing
The C-natriuretic peptide (CNP) analog vosoritide recently became the first drug approved for the treatment of achondroplasia in children, clearly a significant milestone in the history of this rare disease. However, the dosing regimen is very burdensome for the young patients, requiring daily subcutaneous injections for potentially more than a decade. At ProLynx, using our half-life extension technology we have developed a long-acting CNP analog conjugate that demonstrates equal or greater efficacy to vosoritide while at the same time requiring less frequent, more convenient dosing. Our half-life extension technology utilizes β-eliminative linkers to attach a drug to pre-fabricated tetra-polyethylene glycol hydrogel microspheres (tetra-PEG microspheres). When injected subcutaneously, these microspheres act as a stationary depot where the chemistry of the β-eliminative linkers allows for controlled release of the attached drug, which translates directly to control of the plasma half-life. Two microsphere conjugates were prepared with release rates designed to allow once-weekly and once-monthly administration using a highly active, deamidation resistant CNP analog, [Gln 6,14]CNP-38. In vitro studies in mice demonstrated that [Gln 6,14]CNP-38 was slowly released from the conjugates into the systemic circulation with biphasic elimination pharmacokinetics and terminal half-lives of ∼200 h and ∼600 h. In addition, studies in mice using weekly to monthly dosing regimens demonstrated growth comparable to or exceeding daily injections of vosoritide. Further studies in cynomolgus monkeys showed a similarly extended terminal half-live of ~600 h. Simulations of the human pharmacokinetics indicate that plasma levels of [Gln 6,14]CNP-38 could be maintained within the required therapeutic window for monthly dosing intervals, significantly reducing the patient burden from ~30 injections per month to one.
- Open Access
- 18 July 2022
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 119 (30)
A long-acting C-natriuretic peptide for achondroplasia
The C-natriuretic peptide (CNP) analog vosoritide has recently been approved for treatment of achondroplasia in children. However, the regimen requires daily subcutaneous injections in pediatric patients over multiple years. The present work sought to develop a long-acting CNP that would provide efficacy equal to or greater than that of vosoritide but require less frequent injections. We used a technology for half-life extension, whereby a drug is attached to tetra-polyethylene glycol hydrogels (tetra-PEG) by β-eliminative linkers that cleave at predetermined rates. These hydrogels—fabricated as uniform ∼60-μm microspheres—are injected subcutaneously, where they serve as a stationary depot to slowly release the drug into the systemic circulation. We prepared a highly active, stable CNP analog—[Gln6,14]CNP-38—composed of the 38 C-terminal amino acids of human CNP-53 containing Asn to Gln substitutions to preclude degradative deamidation. Two microsphere [Gln6,14]CNP-38 conjugates were prepared, with release rates designed to allow once-weekly and once-monthly administration. After subcutaneous injection of the conjugates in mice, [Gln6,14]CNP-38 was slowly released into the systemic circulation and showed biphasic elimination pharmacokinetics with terminal half-lives of ∼200 and ∼600 h. Both preparations increased growth of mice comparable to or exceeding that produced by daily vosoritide. Simulations of the pharmacokinetics in humans indicated that plasma [Gln6,14]CNP-38 levels should be maintained within a therapeutic window over weekly, biweekly, and likely, monthly dosing intervals. Compared with vosoritide, which requires ∼30 injections per month, microsphere [Gln6,14]CNP-38 conjugates—especially the biweekly and monthly dosing—could provide an alternative that would be well accepted by physicians, patients, and patient caregivers.
- 18 July 2022
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 119 (30)
Open AccessA long-acting C-natriuretic peptide for achondroplasia
The C-natriuretic peptide (CNP) analog vosoritide has recently been approved for treatment of achondroplasia in children. However, the regimen requires daily subcutaneous injections in pediatric patients over multiple years. The present work sought to develop a long-acting CNP that would provide efficacy equal to or greater than that of vosoritide but require less frequent injections. We used a technology for half-life extension, whereby a drug is attached to tetra-polyethylene glycol hydrogels (tetra-PEG) by β-eliminative linkers that cleave at predetermined rates. These hydrogels—fabricated as uniform ∼60-μm microspheres—are injected subcutaneously, where they serve as a stationary depot to slowly release the drug into the systemic circulation. We prepared a highly active, stable CNP analog—[Gln6,14]CNP-38—composed of the 38 C-terminal amino acids of human CNP-53 containing Asn to Gln substitutions to preclude degradative deamidation. Two microsphere [Gln6,14]CNP-38 conjugates were prepared, with release rates designed to allow once-weekly and once-monthly administration. After subcutaneous injection of the conjugates in mice, [Gln6,14]CNP-38 was slowly released into the systemic circulation and showed biphasic elimination pharmacokinetics with terminal half-lives of ∼200 and ∼600 h. Both preparations increased growth of mice comparable to or exceeding that produced by daily vosoritide. Simulations of the pharmacokinetics in humans indicated that plasma [Gln6,14]CNP-38 levels should be maintained within a therapeutic window over weekly, biweekly, and likely, monthly dosing intervals. Compared with vosoritide, which requires ∼30 injections per month, microsphere [Gln6,14]CNP-38 conjugates—especially the biweekly and monthly dosing—could provide an alternative that would be well accepted by physicians, patients, and patient caregivers.
- 6 April 2021
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 32 (4) , 794-800
Attenuation of the Reaction of Michael Acceptors with Biologically Important Nucleophiles
β-Elimination of drugs tethered to macromolecular carbamates provides a platform for drug half-life extension. However, the macromolecular Michael acceptor products formed upon drug release can potentially react with biological amines and thiols and may raise concerns about safety. We desired to mitigate this possibility by developing linkers that have predictable rates of β-elimination but suppressed rates of nucleophilic addition to their Michael acceptor products. We prepared Michael acceptor products of β-eliminative linkers that contained a methyl group at the Cβ carbon or a gem-dimethyl group at the Cγ carbon and studied the kinetics of their reactions with the most prevalent biological nucleophiles—amine and thiol groups. Aza-Michael reactions with glycine are slowed about 20-fold by methylation of the β-carbon and 175-fold with a gem-dimethyl group at the γ-carbon. Likewise, addition of the glutathione thiol to γ-gem-dimethyl Michael acceptors was retarded 7–24-fold compared to parent unsubstituted linkers. It was estimated that in an in vivo environment of ∼0.5 mM macromolecular thiols or ∼20 mM macromolecular amines—as in plasma—the reaction half-life of a typical Michael acceptor with a γ-gem-dimethyl linker could exceed 3 years for thiols or 25 years for amines. We also prepared a large series of γ-gem-dimethyl β-eliminative linkers and showed excellent structure–activity relationships of elimination rates with corresponding unsubstituted parent linkers. Finally, we compared the first-generation unsubstituted and new gem-dimethyl β-eliminative linkers in a once-monthly drug delivery system of a 39 amino acid peptide. Both linkers provided the desired half-life extension of the peptide, but the Michael acceptor formed from the gem-dimethyl linker was much less reactive. We conclude that the γ-gem-dimethyl β-eliminative linkers provide high flexibility and greatly reduce potential reactions of Michael acceptor products with biologically important nucleophiles.
- 6 April 2021
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 32 (4) , 794-800
Attenuation of the Reaction of Michael Acceptors with Biologically Important Nucleophiles
β-Elimination of drugs tethered to macromolecular carbamates provides a platform for drug half-life extension. However, the macromolecular Michael acceptor products formed upon drug release can potentially react with biological amines and thiols and may raise concerns about safety. We desired to mitigate this possibility by developing linkers that have predictable rates of β-elimination but suppressed rates of nucleophilic addition to their Michael acceptor products. We prepared Michael acceptor products of β-eliminative linkers that contained a methyl group at the Cβ carbon or a gem-dimethyl group at the Cγ carbon and studied the kinetics of their reactions with the most prevalent biological nucleophiles—amine and thiol groups. Aza-Michael reactions with glycine are slowed about 20-fold by methylation of the β-carbon and 175-fold with a gem-dimethyl group at the γ-carbon. Likewise, addition of the glutathione thiol to γ-gem-dimethyl Michael acceptors was retarded 7–24-fold compared to parent unsubstituted linkers. It was estimated that in an in vivo environment of ∼0.5 mM macromolecular thiols or ∼20 mM macromolecular amines—as in plasma—the reaction half-life of a typical Michael acceptor with a γ-gem-dimethyl linker could exceed 3 years for thiols or 25 years for amines. We also prepared a large series of γ-gem-dimethyl β-eliminative linkers and showed excellent structure–activity relationships of elimination rates with corresponding unsubstituted parent linkers. Finally, we compared the first-generation unsubstituted and new gem-dimethyl β-eliminative linkers in a once-monthly drug delivery system of a 39 amino acid peptide. Both linkers provided the desired half-life extension of the peptide, but the Michael acceptor formed from the gem-dimethyl linker was much less reactive. We conclude that the γ-gem-dimethyl β-eliminative linkers provide high flexibility and greatly reduce potential reactions of Michael acceptor products with biologically important nucleophiles.
- 1 September 2017
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 117 (09) , 1750-1760
Analysis of the substrate specificity of Factor VII activating protease (FSAP) and design of specific and sensitive peptide substrates
Factor VII (FVII) activating protease (FSAP) is a circulating serine protease that is likely to be involved in a number of disease conditions such as stroke, atherosclerosis, liver fibrosis, thrombosis and cancer. To date, no systematic information is available about the substrate specificity of FSAP. Applying phage display and positional scanning substrate combinatorial library (PS-SCL) approaches we have characterised the specificity of FSAP towards small peptides. Results were evaluated in the context of known protein substrates as well as molecular modelling of the peptides in the active site of FSAP. The representative FSAP-cleaved sequence obtained from the phage display method was Val-Leu-Lys-Arg-Ser (P4-P1’). The sequence X-Lys/Arg-Nle-Lys/Arg (P4-P1) was derived from the PS-SCL method. These results show a predilection for cleavage at a cluster of basic amino acids on the nonprime side. Quenched fluorescent substrate (Ala-Lys-Nle-Arg-AMC) (amino methyl coumarin) and (Ala-Leu-Lys-Arg-AMC) had a higher selectivity for FSAP compared to other proteases from the hemostasis system. These substrates could be used to measure FSAP activity in a complex biological system such as plasma. In histonetreated plasma there was a specific activation of pro-FSAP as validated by the use of an FSAP inhibitory antibody, corn trypsin inhibitor to inhibit Factor XIIa and hirudin to inhibit thrombin, which may account for some of the haemostasis-related effects of histones. These results will aid the development of further selective FSAP activity probes as well as specific inhibitors that will help to increase the understanding of the functions of FSAP in vivo. Supplementary Material to this article is available online at www.thrombosis-online.com.
- 1 September 2017
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 117 (09) , 1750-1760
Analysis of the substrate specificity of Factor VII activating protease (FSAP) and design of specific and sensitive peptide substrates
Factor VII (FVII) activating protease (FSAP) is a circulating serine protease that is likely to be involved in a number of disease conditions such as stroke, atherosclerosis, liver fibrosis, thrombosis and cancer. To date, no systematic information is available about the substrate specificity of FSAP. Applying phage display and positional scanning substrate combinatorial library (PS-SCL) approaches we have characterised the specificity of FSAP towards small peptides. Results were evaluated in the context of known protein substrates as well as molecular modelling of the peptides in the active site of FSAP. The representative FSAP-cleaved sequence obtained from the phage display method was Val-Leu-Lys-Arg-Ser (P4-P1’). The sequence X-Lys/Arg-Nle-Lys/Arg (P4-P1) was derived from the PS-SCL method. These results show a predilection for cleavage at a cluster of basic amino acids on the nonprime side. Quenched fluorescent substrate (Ala-Lys-Nle-Arg-AMC) (amino methyl coumarin) and (Ala-Leu-Lys-Arg-AMC) had a higher selectivity for FSAP compared to other proteases from the hemostasis system. These substrates could be used to measure FSAP activity in a complex biological system such as plasma. In histonetreated plasma there was a specific activation of pro-FSAP as validated by the use of an FSAP inhibitory antibody, corn trypsin inhibitor to inhibit Factor XIIa and hirudin to inhibit thrombin, which may account for some of the haemostasis-related effects of histones. These results will aid the development of further selective FSAP activity probes as well as specific inhibitors that will help to increase the understanding of the functions of FSAP in vivo. Supplementary Material to this article is available online at www.thrombosis-online.com.
- 29 June 2017
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 12 (8) , 2107-2116
A Hydrogel-Microsphere Drug Delivery System That Supports Once-Monthly Administration of a GLP-1 Receptor Agonist
We have developed a chemically controlled very long-acting delivery system to support once-monthly administration of a peptidic GLP-1R agonist. Initially, the prototypical GLP-1R agonist exenatide was covalently attached to hydrogel microspheres by a self-cleaving β-eliminative linker; after subcutaneous injection in rats, the peptide was slowly released into the systemic circulation. However, the short serum exenatide half-life suggested its degradation in the subcutaneous depot. We found that exenatide undergoes deamidation at Asn28 with an in vitro and in vivo half-life of approximately 2 weeks. The [Gln28]exenatide variant and exenatide showed indistinguishable GLP-1R agonist activities as well as pharmacokinetic and pharmacodynamic effects in rodents; however, unlike exenatide, [Gln28]exenatide is stable for long periods. Two different hydrogel-[Gln28]exenatide conjugates were prepared using β-eliminative linkers with different cleavage rates. After subcutaneous injection in rodents, the serum half-lives for the released [Gln28]exenatide from the two conjugates were about 2 weeks and one month. Two monthly injections of the latter in the Zucker diabetic fatty rat showed pharmacodynamic effects indistinguishable from two months of continuously infused exenatide. Pharmacokinetic simulations indicate that the delivery system should serve well as a once-monthly GLP-1R agonist for treatment of type 2 diabetes in humans.
- 29 June 2017
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 12 (8) , 2107-2116
A Hydrogel-Microsphere Drug Delivery System That Supports Once-Monthly Administration of a GLP-1 Receptor Agonist
We have developed a chemically controlled very long-acting delivery system to support once-monthly administration of a peptidic GLP-1R agonist. Initially, the prototypical GLP-1R agonist exenatide was covalently attached to hydrogel microspheres by a self-cleaving β-eliminative linker; after subcutaneous injection in rats, the peptide was slowly released into the systemic circulation. However, the short serum exenatide half-life suggested its degradation in the subcutaneous depot. We found that exenatide undergoes deamidation at Asn28 with an in vitro and in vivo half-life of approximately 2 weeks. The [Gln28]exenatide variant and exenatide showed indistinguishable GLP-1R agonist activities as well as pharmacokinetic and pharmacodynamic effects in rodents; however, unlike exenatide, [Gln28]exenatide is stable for long periods. Two different hydrogel-[Gln28]exenatide conjugates were prepared using β-eliminative linkers with different cleavage rates. After subcutaneous injection in rodents, the serum half-lives for the released [Gln28]exenatide from the two conjugates were about 2 weeks and one month. Two monthly injections of the latter in the Zucker diabetic fatty rat showed pharmacodynamic effects indistinguishable from two months of continuously infused exenatide. Pharmacokinetic simulations indicate that the delivery system should serve well as a once-monthly GLP-1R agonist for treatment of type 2 diabetes in humans.
- 7 October 2016
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 27 (10) , 2534-2539
Approach for Half-Life Extension of Small Antibody Fragments That Does Not Affect Tissue Uptake
The utility of antigen-binding antibody fragments is often limited by their short half-lives. Half-life extension of such fragments is usually accomplished by attachment or binding to high-molecular-weight carriers that reduce the renal elimination rate. However, the higher hydrodynamic radius results in greater confinement in the vascular compartment and, thus, lower tissue distribution. We have developed a chemically controlled drug delivery system in which the drug is covalently attached to hydrogel microspheres by a self-cleaving β-eliminative linker; upon subcutaneous injection, the t1/2,β of the released drug acquires the t1/2 of linker cleavage. In the present work, we compared the pharmacokinetics of an anti-TNFα scFv, the same scFv attached to 40 kDa PEG by a stable linker, and the scFv attached to hydrogel microspheres by a self-cleaving linker. We also developed a general approach for the selective attachment of β-eliminative linkers to the N-termini of proteins. In rats, the scFv had a t1/2,β of 4 h and a high volume of distribution at steady state (Vd,SS), suggesting extensive tissue distribution. The PEG–scFv conjugate had an increased t1/2,β of about 2 days but showed a reduced Vd,SS that was similar to the plasma volume. In contrast, the tissue-penetrable scFv released from the hydrogel system had a t1/2,β of about 2 weeks. Thus, the cleavable microsphere–scFv conjugate releases its protein cargo with a prolonged half-life comparable to that of most full-length mAbs and in a form that has the high tissue distribution characteristic of smaller mAb fragments. Other antigen-binding antibody fragments should be amenable to the half-life extension approach described here.
- 7 October 2016
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 27 (10) , 2534-2539
Approach for Half-Life Extension of Small Antibody Fragments That Does Not Affect Tissue Uptake
The utility of antigen-binding antibody fragments is often limited by their short half-lives. Half-life extension of such fragments is usually accomplished by attachment or binding to high-molecular-weight carriers that reduce the renal elimination rate. However, the higher hydrodynamic radius results in greater confinement in the vascular compartment and, thus, lower tissue distribution. We have developed a chemically controlled drug delivery system in which the drug is covalently attached to hydrogel microspheres by a self-cleaving β-eliminative linker; upon subcutaneous injection, the t1/2,β of the released drug acquires the t1/2 of linker cleavage. In the present work, we compared the pharmacokinetics of an anti-TNFα scFv, the same scFv attached to 40 kDa PEG by a stable linker, and the scFv attached to hydrogel microspheres by a self-cleaving linker. We also developed a general approach for the selective attachment of β-eliminative linkers to the N-termini of proteins. In rats, the scFv had a t1/2,β of 4 h and a high volume of distribution at steady state (Vd,SS), suggesting extensive tissue distribution. The PEG–scFv conjugate had an increased t1/2,β of about 2 days but showed a reduced Vd,SS that was similar to the plasma volume. In contrast, the tissue-penetrable scFv released from the hydrogel system had a t1/2,β of about 2 weeks. Thus, the cleavable microsphere–scFv conjugate releases its protein cargo with a prolonged half-life comparable to that of most full-length mAbs and in a form that has the high tissue distribution characteristic of smaller mAb fragments. Other antigen-binding antibody fragments should be amenable to the half-life extension approach described here.